Infosys co-founders chip in to shelter flood-hit victimsOctober 9th, 2009 BANGALORE - Four co-founders of IT bellwether Infosys Technologies collectively contributed Rs.10 crore to rebuild houses for the victims of flood havoc in north Karnataka recently, a top official said. "The company has pledged Rs.20 crore while four co-founders have volunteered to contribute Rs.2.5 crore each to the effort to build 3,000 pucca (permanent) houses for the flood-affected people," Infosys chief executive S.
Infosys, Biocon to build houses for flood-hit in KarnatakaOctober 8th, 2009 BANGALORE - India's IT bellwether Infosys Technologies Ltd and biotechnology major Biocon Ltd pledged to re-build around 6,000 houses at a cost of Rs.60 crore for the flood-affected people of north Karnataka, Chief Minister B.S. Yeddyurappa said Thursday.
Indra Nooyi heads list of top 50 women in world businessSeptember 28th, 2009 LONDON - PepsiCo Chairman and Chief Executive Indra Nooyi of India has topped the inaugural Financial Times (FT) list of top 50 women in world business. Nooyi, 53, is among four Indians making it to a list that FT said prompts the question whether the struggling male-dominated world of business would have been better off with more women in charge.
Sonia Gandhi, Kochhar, Nooyi in Forbes 100 powerful women listAugust 20th, 2009 NEW YORK - Congress party president Sonia Gandhi, PepsiCo chief executive Indra Nooyi and ICICI Bank's new head Chanda Kochhar have been listed among the world's 100 most powerful women by Forbes magazine. All three of them have been ranked higher than US Secretary of State Hillary Clinton on the list, which has German Chancellor Angela Merkel at the top, followed by US Federal Deposit Insurance chairperson Sheila Bair.
Biocon net up 59 percent in first quarterJuly 23rd, 2009 BANGALORE - Biotech major Biocon has posted a net profit of Rs.47.6 crore for the first quarter this fiscal, registering a 59 percent year-on-year (YoY), the company said Thursday. Total income for the quarter under review, however, grew only nine percent YoY to Rs.259 crore from Rs.237 crore in the like period a year ago, the company said in a regulatory filing.
Budget should incentivise biotech sector: Kiran Mazumdar-ShawJuly 5th, 2009 BANGALORE - As a sunrise industry, the biotechnology sector is looking up to the national budget, to be presented in parliament by Finance Minister Pranab Mukherjee Monday, for a fillip in times of global recession and slowdown in the Indian economy. The government must incentivise R&D (research and development), especially in the biotechnology sector by providing a tax holiday for five years on any new product developed in-house, Biocon India chairperson Kiran Mazumdar-Shaw told IANS here.
Biocon announces strategic collaboration with MylanJune 29th, 2009 BANGALORE - Biocon Limited today announced that it has executed a definitive agreement with Mylan Inc. for an exclusive collaboration on the development, manufacturing, supply and commercialization of multiple, high value generic biologic compounds for the global marketplace.
Indian biotech industry growing, but at slower paceJune 18th, 2009 BANGALORE - Global recession and slowdown in the domestic market impacted the Indian biotech industry last fiscal, resulting in a year-on-year (YoY) growth declining to 18 percent from 34 percent notched in 2007-08. According to data released Thursday at Bangalore Bio 2009, India's premier biotech event, the industry grew to Rs.12,137 crore from Rs.10,274 crore the previous fiscal, reflecting an increase of 18 percent.
Biocon to fund innovation cell at Hyderabad B-schoolJune 8th, 2009 BANGALORE - India's biotechnology major Biocon Ltd. Monday announced the setting up of a cell for innovation management at Hyderabad's Indian School of Business (ISB) with a corpus of Rs.1 crore.
Kiran Mazumdar Shaw awarded prestigious 'Nikkei Asia Prize' 2009May 11th, 2009 BANGALORE - Kiran Mazumdar Shaw, Chairman and Managing Director, Biocon Limited has been honoured with the 'Nikkei Asia Prize' 2009 for Regional Growth. Japan's prestigious business daily Nihon Keizai Shimbun (Nikkei) awards Nikkei Asia Prizes annually to individuals or institutions from Asia Pacific region recognizing outstanding achievements that improve the quality of life in Asia.
Biocon last quarter profit dips 61 percentApril 28th, 2009 BANGALORE - Biotechnology major Biocon Tuesday announced a decrease of over 61 percent in its net profit for the quarter ending March 31. In a regulatory statement, Biocon said its unaudited net profit for the last quarter was Rs.241.4 million, compared to Rs.620.3 million - a decrease of over 61 percent.
Biocon Group delivers 16 per cent growth in operating profitsApril 28th, 2009 BANGALORE - Biocon Limited today announced its financial performance for the financial year ended March 31. Unpredictable rupee depreciation induced by the global economic crisis has adversely impacted consolidated FY '09 earnings, wherein losses of Rs.
Weak rupee lowers Biocon net profit 80 percent in 2008-09April 28th, 2009 BANGALORE - A steady weakening of the rupee in the volatile currency market has lowered the consolidated net profit of biotechnology major Biocon group to Rs.93.1 crore in 2008-09 from Rs.464 crore the year before, registering a whopping decline of 80 percent. 'Unpredictable rupee depreciation induced by global economic crisis has adversely impacted our consolidated earnings wherein losses of Rs.147 crore on account of mark-to-market (MTM) were provided,' Biocon chairperson Kiran Mazumdar-Shaw told reporters here Tuesday.
Government launches India Innovation InitiativeApril 6th, 2009 NEW DELHI - The Department of Science and Technology (DST) Monday launched the India Innovation Initiative (i3) in collaboration with the Confederation of Indian Industry (CII) and communication analyst Agilent Technologies. Under the initiative, DST will launch a nation-wide competition of technology-based ideas in which innovators above 18 years of age can participate.
Bristol-Myers Squibb, Biocon's Syngene open new R and D facility at Biocon ParkMarch 23rd, 2009 BANGALORE - Syngene International, a subsidiary of Indian biotechnology major, BIOCON Ltd, and Bristol-Myers Squibb Company announced today the opening of a fully dedicated research and development facility for Bristol-Myers Squibb in Biocon Park, Bangalore. The 200,000 square-foot facility at Biocon Park is dedicated to helping advance Bristol-Myers Squibb's work in discovery and early drug development, and is currently occupied by 270 researchers.